| Literature DB >> 34345575 |
Henry T Shu1, Ahmed H Elhessy2, Janet D Conway2, Arthur L Burnett3, Babar Shafiq1.
Abstract
Objectives: The purpose of this case series is to describe the orthopedic management of pubic symphysis osteomyelitis with an emphasis on the key principles of treating bony infection. Furthermore, we sought to identify whether debridement of the pubic symphysis without subsequent internal fixation would result in pelvic instability.Entities:
Year: 2021 PMID: 34345575 PMCID: PMC8320518 DOI: 10.5194/jbji-6-273-2021
Source DB: PubMed Journal: J Bone Jt Infect ISSN: 2206-3552
Patient data.
| Patient | Sex | Age at index | Previous | Presenting | Surgical | Surgical | Postoperative | Postoperative systemic | Status at |
|---|---|---|---|---|---|---|---|---|---|
| ID | procedure | urological | symptoms | treatment | cultures | complications | antibiotic therapy | final | |
| (years) | treatment | follow-up | |||||||
| 1 | Male | 88 | Radiation therapy for prostate cancer | Tenderness over the pubic symphysis and pain with ambulation | Resection/debridement of pubic symphysis and placement ofvancomycin- andtobramycin-impregnated PMMA beads | Coagulase-negative | None | 10 weeks of IV vancomycin with goaltrough of 13–17 mcg per mL, oral fluconazole 800 mg loading dose followed by oral fluconazole 400 mg daily for 6 weeks | Symptom free,ambulating well |
| 2 | Male | 70 | Urethral reconstructive surgery for urethral stricture | Tenderness over the pubic symphysis and pain with ambulation | Resection/debridement of pubic symphysis and placement ofvancomycin- andtobramycin-impregnated PMMA beads | None | 6 weeks of oralciprofloxacin 750 mgBID and oral fluconazole 800 mg loading dose followed by oral fluconazole 400 mg daily | Symptom free, ambulating well | |
| 3 | Male | 76 | Radiation therapy for prostate cancer | Tenderness over the pubic symphysis and pain with ambulation | Resection/debridement of pubic symphysis and placement of vancomycin- andtobramycin-impregnated PMMA beads | None | 6 weeks of IV piperacillin/tazobactam 3.375 g every 6 h | Symptom free,ambulating well | |
| 4 | Male | 82 | Radiation therapy for prostate cancer | Tenderness over the pubic symphysis and pain with ambulation | Resection/debridement of pubic symphysis and placement ofpowdered vancomycin | None | 6 weeks of IV ceftriaxone 2 g daily | Symptom free, ambulating well | |
| 5 | Female | 61 | None | Tenderness over the pubic symphysis and pain with ambulation | Resection/debridement of pubic symphysiswithout local antibiotics | No growth | Hematuria at the completion of the case requiring a retrograde cystogram documenting a very small leak between the bladder and the drain. Postoperative wound discharge with positivecultures for vancomycin-resistant | 6 weeks of IV ceftriaxone 2 g daily and IV clindamycin 600 mg every 8 h. Then startedon oral Sulfamethoxazole/Trimethoprim 800 mg/160 mg BID and oral Metronidazole 500 mg TID for another 6 weeks. At 8 weeks postoperatively, she was also started on oral linezolid 400 mg BID for suspected diverticulitis for another 4 weeks. | Symptom free, ambulating well |
| 6 | Male | 81 | Radiation therapy for prostate cancer | Tenderness over the pubic symphysis and pain with ambulation | Resection/debridement of pubic symphysis and placement ofvancomycin- andtobramycin-impregnated PMMA beads | Methicillin-resistant | None | 4 weeks of IV linezolid 600 mg BID followed by oral ciprofloxacin 500 mg BID for another 4 weeks | Symptom free,ambulating well |
IV: intravenous, BID: bis in die (twice a day), TID: ter in die (three times a day).
Radiographic outcomes.
| Immediate postoperative | Last | Mean | ||
|---|---|---|---|---|
| radiograph | radiograph | change | ||
| Pubic symphysis diastasis | 27.5 | 32.5 | 5.0 | 0.221 |
| Right sacroiliac joint diastasis | 3.3 | 3.1 | 0.529 | |
| Left sacroiliac joint diastasis | 3.4 | 2.8 | 0.186 |
All measurements are in millimeters (mm). All values reported as mean standard deviation.
Subjective outcome measures
| Mean preoperative | Mean last | Mean | ||
|---|---|---|---|---|
| score | follow-up score | change | ||
| NPRS | 7.5 | 1.9 | 0.020 | |
| SF-36 | ||||
| Physical functioning | 24.0 | 77.0 | 53.0 | 0.032 |
| Role limitations due to physical health | 0.0 | 70.0 | 70.0 | 0.019 |
| Role limitations due to emotional problems | 6.7 | 53.3 | 46.7 | 0.052 |
| Energy/fatigue | 25.0 | 60.0 | 35.0 | 0.023 |
| Emotional well-being | 36.0 | 81.6 | 45.6 | 0.020 |
| Social functioning | 35.0 | 85.0 | 50.0 | 0.016 |
| Pain | 22.0 | 75.5 | 53.5 | 0.008 |
| General health | 39.0 | 70.0 | 31 | 0.021 |
| Health change | 0.0 | 95.0 | 95.0 |
NPRS: numerical pain rating score. All values reported as mean standard deviation.